



23 July 2013

Companies Announcement Office  
ASX Limited  
Exchange Centre  
Level 4, 20 Bridge Street  
Sydney, NSW 2000

**Molecular Discovery Systems Pty Ltd – Australian Patents Granted for  
HLS5 Portfolio**

Please find attached an operational update from BPH Energy Ltd (**ASX: BPH**) investee company Molecular Discovery Systems Ltd.

Yours sincerely,

A handwritten signature in blue ink, appearing to read "D Ambrosini".

Deborah Ambrosini  
Director and Company Secretary



23 July 2013

BPH Energy Limited  
14 View Street  
North Perth, WA 6006

## **Australian Patents Granted for HLS5 Patent Portfolio**

Molecular Discovery Systems Ltd (“**MDS**”), an investee company of BPH Energy Limited (ASX:**BPH**), is pleased to provide the following update on its HLS5 patent portfolio.

Two new patent applications have been granted within Australia, increasing the total of Australian patents granted to four. The issued patents entitled ‘Agent for the treatment of hormone-dependent disorders and uses thereof’ and ‘Transcription Factor modulator’ are valid to March 2027 and April 2027, respectively. The two patents compliment MDS’ previously granted patents ‘Tumour suppressor factor’, which has been granted in the United States and Australia, and the Australian patent entitled ‘Sumoylation control agent and uses thereof’.

MDS has an extensive patent portfolio for HLS5 which encapsulates the gene both as a potential cancer therapeutic target and also underpinning its involvement in a variety of other diseases. In recognition of its potential for detecting and treating cancer; outstanding organisations such as the National Health and Medical Research Council, the Cancer Council of WA, the National Breast Cancer Foundation, the Medical Research Foundation of Royal Perth Hospital and the Scott Kirkbride Melanoma Research Centre have awarded HLS5 research with high-priority funding. MDS will continue working with Professor Peter Klinken and his research group at the Western Australian Institute for Medical Research (WAIMR) with the aim of developing the HLS5 research to its full potential.

Patent applications relating to the HLS5 gene are progressing in Australia, Europe and the US.

Yours sincerely,

A handwritten signature in black ink, appearing to read 'D. Breeze', with a stylized flourish at the end.

David Breeze  
Chairman

**Molecular Discovery Systems Pty Ltd**

ACN 118 494 492

PO Box 317, North Perth, Western Australia 6906

14 View Street, North Perth, Western Australia 6006

admin@mdsystems.com.au www.mdsystems.com.au

T: +61 8 9328 8644 F: +61 8 9328 8733